Class Action Investor Rights Class Action Lawsuits Fraud Corporate Law Shareholder Rights Class Actions Investor Protection Corporate Governance Regulatory Compliance
The case centers on claims that MoonLake overstated sonelokimab’s Nanobody advantages, with the Phase 3 VELA readout undercutting those statements.